Bandingkan Harga & Kinerja Sanurhasta Mitra Tbk. (MINA) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Sanurhasta Mitra Tbk. dan Organon Pharma Indonesia Tbk.: Sanurhasta Mitra Tbk. diperdagangkan di Rp274 (kapitalisasi pasar 2,7 T, volume 24 jam 55,12 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Sanurhasta Mitra Tbk. jauh lebih besar — sekitar 25,9× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| MINA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 2,7 T | 104,4 M |
Volume | 55,12 jt | — |
Lot | 551,16 rb | — |
Perputaran | 14,92 M | — |
Harga Rata-rata | 270,69 | — |
Nilai Transaksi | 14,92 M | — |
Harga Ekuilibrium Indikatif | 274 | — |
Volume Ekuilibrium Indikatif | 6,22 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Sanurhasta Mitra Tbk.
PT Sanurhasta Mitra (the Company) was established on December 29, 1993 by Notarial Deed No. 196 of Ny. Pudji Redjeki Irawati, S.H., Notary in Jakarta and has been corrected by notarial deed No. 32 dated August 5, 1994 by the Notary substitute Drs. Sutjahjo Srudji, S.H., Notary in Jakarta. PT Sanurhasta Mitra as the shareholder of PT Minna Padi Resorts, also has its own business on The Santai, a very luxurious style villa for your family vacation that has been operated by Lifestyle Retreats Pte. Ltd. Within the resort concept. The Santai surrounded with rice field and the quiet rural ambience.
Selengkapnya di halaman MINA →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
